Lobectomy After Induction Therapy for Stage IIIA NSCLC in the Presence of Persistent N2 Disease

  • Gaetano Rocco


Involvement of mediastinal nodes by metastatic deposits from non-small cell lung cancer (NSCLC) is characterized by heterogeneous manifestations and diverse clinical scenarios (Table 11.1).1,2 For many of these N2 subsets the therapeutic options are well known and are accepted in the clinical practice.3 Patients with potentially resectable N2 disease detected preoperatively usually undergo induction treatment (chemotherapy and/or chemoradiotherapy) and subsequent resection if they show a clinical or pathological complete response.4 Conversely, patients with technically unresectable NSCLC and N2 disease are treated with definitive chemoradiotherapy.5 When N2 disease is discovered only at final pathology, an adjuvant chemoradiation therapeutic regimen is proposed.4,5


  1. 1.
    Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, Brouchet L, Quoix E, Westeel V, Le Chevalier T. Survival of patients with resected N2 non–small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18: 2981–2989.PubMedGoogle Scholar
  2. 2.
    Johnson DH, Rusch VW, Turrisi AT. Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non–small-cell lung cancer. JNCI. 2007;99:415–418.PubMedCrossRefGoogle Scholar
  3. 3.
    van Meerbeeck JP, Surmont VFM Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments. Lung Cancer. 2009;65:257–267.PubMedCrossRefGoogle Scholar
  4. 4.
    Tieu BH, Sanborn RE, Thomas CR. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement. Thorac Surg Clin. 2008;18:403–415.PubMedCrossRefGoogle Scholar
  5. 5.
    Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW. Treatment of non-small cell lung cancer-stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines, 2nd ed. Chest. 2007;132(suppl 3):243S–265.PubMedCrossRefGoogle Scholar
  6. 6.
    Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA Non-Small Cell Lung Cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg. 2008;86:912–920.PubMedCrossRefGoogle Scholar
  7. 7.
    Port JL, Korst RJ, Lee PC, Levin MA, Becker DE, Roger Keresztes, Altorki NK. Surgical resection for residual N2 disease after induction chemotherapy. Ann Thorac Surg. 2005;79:1686–1690.PubMedCrossRefGoogle Scholar
  8. 8.
    Burdett S, Stewart L, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer: a systematic review and meta-analysis of the literature. J Thorac Oncol. 2006;1:611–621.PubMedCrossRefGoogle Scholar
  9. 9.
    van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, van Zandwijk N, Splinter TA, Giaccone G. European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:442–450.PubMedCrossRefGoogle Scholar
  10. 10.
    Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sauze WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer.: a phase III randomized trial. Lancet. 2009;374:379–386.PubMedCrossRefGoogle Scholar
  11. 11.
    Betticher DC, Hsu Schmitz SF, Totsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB, for the Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006;94:1099–1106.PubMedCrossRefGoogle Scholar
  12. 12.
    Garrido P, Gonzalez-Larriba JL, Insa A, Provencio M, Torres A, Isla D, Sanchez JM, Cardenal F, Domine M, Barcelo JR, Tarrazona V, Varela A, Aguilo R, Astudillo J, Muguruza I, Artal A, Hernando-Trancho F, Massuti B, Sanchez-Ronco M, Rosell R. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol. 2007;25:4736–4742.PubMedCrossRefGoogle Scholar
  13. 13.
    Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G, Licker M, Ferguson MK, Faivre-Finn C, Huber RM, Clini EM, Win T, De Ruysscher D, Goldman L; European Respiratory Society; European Society of Thoracic Surgeons Joint Task Force on Fitness For Radical Therapy. The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. Eur J Cardiothorac Surg. 2009;36:181–184.PubMedCrossRefGoogle Scholar
  14. 14.
    Gudbjartsson T, Gyllstedt E, Pikwer A, Jönsson P. Early surgical results after pneumonectomy for non-small cell lung cancer are not affected by preoperative radiotherapy and chemotherapy. Ann Thorac Surg. 2008;86:376–382.PubMedCrossRefGoogle Scholar
  15. 15.
    Doddoli C, Barlesi F, Trousse D, Robitail S, Yena S, Astoul P, Giudicelli R, Fuentes P, Thomas P. One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg. 2005;130:416–425.PubMedCrossRefGoogle Scholar
  16. 16.
    Van Schil P. Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non–small cell lung cancer. J Thorac Cardiovasc Surg. 2008;135:718–719.PubMedCrossRefGoogle Scholar
  17. 17.
    Kunitoch H, Suzuki K. How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small cell lung cancer. Br J Cancer. 2007;96:1498–1503.CrossRefGoogle Scholar
  18. 18.
    Uy KL, Darling G, Xu W, Yi QL, De Perrot M, Pierre AF, Waddell TK, Johnston MR, Bezjak A, Shepherd FA, Keshavjee S. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non–small cell lung cancer. J Thorac Cardiovasc Surg. 2007;134:188–193.PubMedCrossRefGoogle Scholar
  19. 19.
    Siegenthaler M, Pisters K, Merriman K et al. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg. 2001;71:1105–1112.PubMedCrossRefGoogle Scholar
  20. 20.
    Perrot E, Guibert B, Mulsant P et al. Preoperative chemotherapy does not increase complications after non-small cell lung cancer resection. Ann Thorac Surg. 2005;80:423–427.PubMedCrossRefGoogle Scholar
  21. 21.
    Burrows WM. Anatomical lung resection after neoadjuvant chemoradiotherapy. Semin Thorac Cardiovasc Surg. 2007;19:360–365.PubMedCrossRefGoogle Scholar
  22. 22.
    Venuta F, Anile M, Diso D, Ibrahim M, De Giacomo T, Rolla M, Liparulo V, Coloni GF. Operative complications and early mortality after induction therapy for lung cancer. Eur J Cardiothorac Surg. 2007;31:714–717.PubMedCrossRefGoogle Scholar
  23. 23.
    Leo F, De Pas T, Catalano G, Piperno G, Curigliano G, Solli P, Veronesi G, Petrella F, Spaggiari L. Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer. J Natl Cancer Inst. 2007;99:1210.PubMedCrossRefGoogle Scholar
  24. 24.
    van Meerbeeck JP, van Schil P, Senan S; EORTC-Lung Cancer Group. Reply: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. J Thorac Oncol. 2007;2:1138–1139.PubMedCrossRefGoogle Scholar
  25. 25.
    Veronesi G, Solli PG, Leo F, D’Aiuto M, Pelosi G, Leon ME, F. De Braud, L. Spaggiari, U. Pastorino. Low morbidity of bronchoplastic procedures after chemotherapy for lung cancer. Lung Cancer. 2002;36:91–97.PubMedCrossRefGoogle Scholar
  26. 26.
    Venuta F, Ciccone AM, Anile M, Ibrahim M, De Giacomo T, Coloni GF, Rendina EA. Reconstruction of the pulmonary artery for lung cancer: long-term results. J Thorac Cardiovasc Surg. 2009:138(5):1185–1191.PubMedCrossRefGoogle Scholar
  27. 27.
    Ohta Y, Shimizu Y, Minato H, Matsumoto I, Oda M, Watanabe G. Results of initial operations in non–small cell lung cancer patients with single-level N2 disease. Ann Thorac Surg. 2006;81:427–433.PubMedCrossRefGoogle Scholar
  28. 28.
    Vansteenkiste J, Betticher D, Eberhardt W, De Leyn P, Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. J Thorac Oncol. 2007;2:684–685.PubMedCrossRefGoogle Scholar
  29. 29.
    Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–3551.PubMedCrossRefGoogle Scholar
  30. 30.
    Girard N, Mornexa F Douillardb J-Y, Bossardd N, Quoixb E, Beckendorfb V, Grunenwald D, Amourb E, Milleron B. Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. doi.org/10.1016/j.lungcan.2009.10.003Google Scholar
  31. 31.
    Kappers I, van Sandick JW, Burgers SA, Belderbos JSA, van Zandwijk N, Klomp HM. Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided. Lung Cancer. 2009; doi 10.1016/j.lungcan.2009.07.001Google Scholar
  32. 32.
    Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax. 2006;61:597–603.PubMedCrossRefGoogle Scholar
  33. 33.
    De Marinis F, Nelli F, Migliorino MR et al. Gemcitabine, paclitaxel,and cisplatin as induction chemotherapy for patients with biopsy-proven stage IIIA(N2) non-small cell lung carcinoma: a phase II multicenter study. Cancer. 2003;98:1707–1715.PubMedCrossRefGoogle Scholar
  34. 34.
    Rocco G. Results of cutting-edge surgery in stage IIIA-N2 nonsmall cell lung cancer. Curr Opin Oncol. 2009;21:105–109.PubMedCrossRefGoogle Scholar
  35. 35.
    Guyatt G, Gutterman D, Baumann MH, Addreizzo-Harris D, Hylek EM, Phillips B, Raskob G, Zelman Lewis S, Schunemann H. Grading strength of recommendations and quality of evidence in clinical guidelines. Chest. 2006;129:174–181.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Gaetano Rocco
    • 1
  1. 1.Department of Thoracic Surgery and OncologyNational Cancer Institute Pascale FoundationNaplesItaly

Personalised recommendations